CLOs on the Move

RTD Company

www.rtdco.com

 
RTD Company is a Andover, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.rtdco.com
  • 15825 Central Ave NE
    Andover, MN USA 55304
  • Phone: 763.689.4870

Executives

Name Title Contact Details

Similar Companies

NotCo

Same taste, but plant-based. A food revolution has started. Know the future of food. Why not?

Genesis Therapeutics

Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D.

Celularity

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity`s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature`s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases.

Notable Labs

Notable Labs is a translationally focused drug development company that uses a clinically validated, automated compound sensitivity platform to identify and advance novel therapeutic candidates to dramatically reduce the cost and time of the traditional drug development process.

Ocera Therapeutics

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease.